Algeta schedules third quarter 2011 results presentation, webcast and conference call
(Thomson Reuters ONE) -
Oslo, Norway, 31 October 2011 - Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, will announce its third
quarter 2011 results on Thursday, 10 November 2011. A presentation by Algeta's
senior management team to investors, analysts and the press will take place in
Oslo at 10:30 CET.
The presentation will also be webcast live and can be accessed from
www.algeta.com/webcast where questions can also be submitted during the
presentation.
The presentation will take place at 10:30 CET at:
Shippingklubben
Haakon VIIs gate 1
0161 Oslo
Norway.
Algeta's senior management will also host an international conference call at
14:30 CET (details below).
To participate in the conference call, please dial the appropriate number below
five minutes prior to the call:
800 80 119 (in Norway)
+47 23 18 45 01 (from abroad)
To access the replay, please dial +47 23 18 45 02. Enter account no. 1428
followed by #, then press 1, conference no. 428 followed by #. Press 1 to play.
A replay version of the conference call will also be available at
www.algeta.com.
The results report and the presentation will be made available on www.algeta.com
in the Investors section from 07:00 CET.
###
For further information, please contact:
Algeta ASA:
Mike Booth +47 2202 4510
Communications & Corporate Affairs ir(at)algeta.com
International media enquiries:
Mark Swallow +44 207 638 9571
Citigate Dewe Rogerson mark.swallow(at)citigatedr.co.uk
US investor enquiries:
Jessica Lloyd +1 646 378 2928
The Trout Group jlloyd(at)troutgroup.com
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting side-
effects.
Alpharadin is being developed under a development and commercialization
agreement with Bayer HealthCare Pharmaceuticals AG. In June 2011, a global phase
III clinical trial (ALSYMPCA) of Alpharadin to treat bone metastases in patients
with castration-resistant prostate cancer (CRPC) was stopped early after meeting
its primary endpoint of significantly improving overall survival. The US Food
and Drug Administration (FDA) has granted Alpharadin Fast Track designation for
this indication. Alpharadin is also under investigation in phase II clinical
trials as a potential new treatment for bone metastases in endocrine-refractory
breast cancer patients, and in a phase I/IIa trial in combination with docetaxel
chemotherapy in for bone metastases CRPC patients.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring frequently in certain late-stage cancers, e.g.
prostate (in up to 90% patients), breast (up to 75%) and lung (up to 40%).
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
pharmaceutical candidates.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. These
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Algeta schedules third quarter 2011 results:
http://hugin.info/134655/R/1559107/482010.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1559107]
Unternehmensinformation / Kurzprofil:
Datum: 31.10.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 81954
Anzahl Zeichen: 6339
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta schedules third quarter 2011 results presentation, webcast and conference call"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
